Truist Financial’s MacroGenics MGNX Stock Holding History

Truist Financial’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-28,572	Closed	-$911K	–	2765
2021 Q1	$911K	Sell	28,572 -4,325	-13%	-$105K	﹤0.01%	1644
2020 Q4	$752K	Buy	32,897 +2,345	+8%	+$54K	﹤0.01%	1649
2020 Q3	$770K	Buy	30,552 +6,400	+26%	+$175K	﹤0.01%	1489
2020 Q2	$674K	Hold	24,152	–	–	﹤0.01%	1461
2020 Q1	$140K	Buy	+24,152	New	+$219K	﹤0.01%	2206

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Truist Financial's MGNX Position: Q2 2021 in Review

Truist Financial sold out of MacroGenics (MGNX) in Q2 2021, closing a stake of 28,572 shares — an estimated $911K sold.

Truist Financial first reported a position in MGNX in Q1 2020 and held it in 5 quarters. The position peaked at $911K in Q1 2021. 149 funds tracked by Wall St. Rank hold MGNX as of Q2 2021.

Truist Financial reported no remaining MacroGenics position as of Q2 2021 after selling out during the quarter.
Truist Financial sold 28,572 MacroGenics shares in Q2 2021, an estimated $911K.
Truist Financial first reported a position in MacroGenics in Q1 2020 and held it in 5 quarters.
Truist Financial's MacroGenics position peaked at $911K in Q1 2021.
149 funds tracked by Wall St. Rank held MacroGenics as of Q2 2021.

Based on Truist Financial's 13F filing for Q2 2021, filed 16 Aug 2021.